%0 Journal Article
%A Blancas, I
%A Fontanillas, M
%A Conde, V
%A Lao, J
%A Martinez, E
%A Sotelo, M J
%A Jaen, A
%A Bayo, J L
%A Carabantes, F
%A Illarramendi, J J
%A Gordon, M M
%A Cruz, J
%A Garcia-Palomo, A
%A Mendiola, C
%A Perez-Ruiz, E
%A Bofill, J S
%A Baena-Cañada, J M
%A Jañez, N M
%A Esquerdo, G
%A Ruiz-Borrego, M
%T Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
%D 2017
%U http://hdl.handle.net/10668/13021
%X Introduction: This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic breast cancer who had disease progression after receiving antiestrogen therapy in clinical practice, gathering real-world data. Materials and methods: A multicenter, retrospective, observational study conducted in Spain. Postmenopausal women with locally advanced/metastatic ER-positive breast cancer who received treatment with fulvestrant 500 mg after progression with a previous anti-estrogen therapy were eligible. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), clinical benefit rate (CBR), duration of clinical benefit (DoCB), and safety profile. Results: A total of 263 women were evaluated (median age, 65.8 years). At a median follow-up of 21.5 months, median PFS and OS were 10.6 and 43.2 months, respectively. PFS according to 1st, 2nd, 3rd, and 4th lines were 11.5, 10.6, 9.9, and 8.5 months, respectively (p = 0.0245). PFS in patients with visceral involvement was 10 months vs 10.6 months in patients without visceral involvement (p = 0.6604), 9.6 months in patients with high Ki67 vs 10 months in patients with low Ki67 (p = 0.7224), and 10.2 months in HER2+ patients vs 10.3 months in HER2- patients (p = 0.6809). The CBR was 56.5% and the DoCB was 18.4 months. The most frequent adverse events were injection site pain (10.3%) and musculoskeletal disorders (7.6%). Conclusions: Fulvestrant 500 mg administered in clinical practice was shown to be effective (PFS, 10.6 months; CBR, 56.5%) and well tolerated, in accordance with previous trials.
%K Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
%K Área de Gestión Sanitaria Sur de Sevilla
%K Metastatic breast cancer
%K Postmenopausal women
%K Hormone receptor-positive advanced breast cancer
%K Fulvestrant
%~